Non-Surgical Treatment of Heavy Menstrual Bleeding from Fibroids: A New Paradigm
World Class CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
World Class CME designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an unrestricted educational grant from Myovant, Inc.
Audience: : This activity was designed for OB/GYN physicians, advanced practitioners in women’s health and primary care providers who diagnose and treat heavy menstrual bleeding from fibroids.
FACULTY
Program Director
Steven R. Goldstein, MD, CCD, NCMP, FACOG
Professor of Obstetrics and Gynecology
New York University Grossman School of Medicine
New York University Langone Medical Center
New York, NY
Author
Scott Chudnoff, MD, MSc, FACOG
Chair, Department of OB/GYN
Maimonides Medical Center
Professor of OBGYN Columbia University
Vagelos School of Physicians and Surgeons
New York, NY
Learning Objectives
At the conclusion of this activity, the participant will be able to:
• Understand mechanism of action of GnRH antagonists
• Appreciate the prevalence and epidemiology of uterine fibroids and heavy menstrual bleeding
• Learners will be able to utilize new or combination of GnRH antagonists with add back therapy for the treatment of heavy menstrual bleeding of fibroids
Date of Original Release: March 1, 2023
Credits Expire: March 1, 2026
CONFLICT OF INTEREST DISCLOSURE
Steven R. Goldstein, MD, CCD, NCMP, FACOG
Advisory Board: Scynexis and Myovant
Consultant: Cook OB/GYN and Cooper Surgical
Recipient of Equipment Loan: GE Ultrasound
Scott Chudnoff, MD, MSc, FACOG
Advisory Board: Cooper Surgical and Myovant,
Investigator: Acessa Gynesonics, Microcube, Bayer, Philips and AEGEA
All of the relevant financial relationships listed for these individuals have been mitigated by peer review completed by peers with no relevant relationships to disclose.
None of the other planners/faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.